接受IL-17A抑制剂治疗的银屑病和银屑病关节炎患者发生新发炎症性肠病的风险：一项基于人群的研究。

Risk of De Novo Inflammatory Bowel Disease in Patients With Psoriasis and Psoriatic Arthritis Treated With IL-17A Inhibitors: A Population-Based Study.

作者信息

Alsakarneh Saqr, Al Ta'ani Omar, Aburumman Razan, Mikhail Inas, Hashash Jana G, Farraye Francis A

机构信息

Department of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.

Department of Medicine, Allegheny Health Network, Pittsburgh, Pennsylvania, USA.

出版信息

Aliment Pharmacol Ther. 2025 Jul;62(1):72-76. doi: 10.1111/apt.70139. Epub 2025 Apr 7.

DOI:10.1111/apt.70139

PMID:40192577

Abstract

IL-17 inhibitors effectively treat psoriasis and psoriatic arthritis but may increase the risk of inflammatory bowel disease (IBD). We assessed their association with IBD compared to apremilast. Utilising the TriNetX database, we analysed patients with psoriasis or ankylosing spondylitis initiating IL-17 inhibitors or apremilast. We used propensity score matching and Cox models to estimate IBD risk. Among 13,216 matched patients per group, 142 developed IBD with IL-17 inhibitors versus 60 with apremilast (aHR = 2.50, 95% CI: 1.85-3.39). IL-17 inhibitors increase IBD risk, necessitating careful patient selection and monitoring.

摘要

白细胞介素-17抑制剂可有效治疗银屑病和银屑病关节炎，但可能会增加炎症性肠病（IBD）的风险。我们评估了它们与阿普斯特相比与IBD的关联。利用TriNetX数据库，我们分析了开始使用白细胞介素-17抑制剂或阿普斯特的银屑病或强直性脊柱炎患者。我们使用倾向评分匹配和Cox模型来估计IBD风险。在每组13216例匹配患者中，使用白细胞介素-17抑制剂的患者中有142例发生IBD，而使用阿普斯特的患者中有60例发生IBD（调整后风险比=2.50，95%置信区间：1.85-3.39）。白细胞介素-17抑制剂会增加IBD风险，因此需要仔细选择患者并进行监测。